Top Markets
#1 龙虾 (Lobster) 龙虾 (Lobster) +114.71%
#2 Lisk Lisk +74.17%
#3 Not in Employment, Education, or Training Not in Employment, Education, or Training +29.93%
#4 Tokenlon Tokenlon +28.92%
#5 Alchemist AI Alchemist AI +25.19%
#6 earnAUSD earnAUSD +24.75%
#7 Nockchain Nockchain +24.71%
#8 Renzo Renzo +22.94%
#9 ARPA ARPA +20.07%
#10 Illuvium Illuvium +18.12%
Coin of the day
龙虾 (Lobster) 龙虾 (Lobster)
Settings
Language
ENGLISH
Currency
USD
Theme
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Rank in Stocks #41009
MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm,... MultiCell Technologies, Inc. (MCET) operates as a biopharmaceutical firm, primarily focused on the creation of innovative therapeutic agents and research tools. Their efforts are directed towards addressing a range of medical challenges, including neurological conditions, liver ailments, various types of cancer, and applications within interventional cardiology and peripheral vascular health. The company's product pipeline features several key developments: MCT-125: This investigational therapy is currently in Phase II clinical trials, targeting the primary fatigue commonly associated with multiple sclerosis. MCT-465: A preclinical-stage synthetic double-stranded RNA (dsRNA) candidate, designed to act as a powerful immune enhancer for the treatment of solid tumor malignancies. MCT-485: Another dsRNA therapeutic, still in the discovery phase, which demonstrates tumor cytolytic (cell-destroying) properties, intended for use against diverse cancers. Beyond drug candidates, MultiCell Technologies is also progressing the Ideal BioStent, an innovative bioabsorbable stent specifically engineered for use in interventional cardiology and peripheral vessel procedures. The organization maintains licensing agreements with prominent entities such as Corning Incorporated and Pfizer Inc. Established in 1962, the company was previously known as Exten Industries, Inc. before officially changing its name to MultiCell Technologies, Inc. in April 2004. Its corporate headquarters are situated in Woonsocket, Rhode Island.
Share Price
$0.00001
Last synced: 2026-09-10
Market Cap
$50.01K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade MultiCell Technologies, Inc. (MCET)

Category

Healthcare
P/E ratio for MultiCell Technologies, Inc. (MCET)
P/E ratio as of September 2026 TTM: -0.10
According to MultiCell Technologies, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.10. At the end of 2013 the company had a P/E ratio of -1.09.
P/E ratio history for MultiCell Technologies, Inc. from 2013 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.10 -97.45%
2014 -3.92 260.77%
2013 -1.09 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -31,538.80%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -36,951.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 17,486.50%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 23,218.60%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.